Wegovy 1mg Results: Why This Dose Isn't the Full Picture

The misconception worth addressing: 1mg is not your Wegovy result

The biggest misreading of semaglutide treatment is treating each dose as a destination rather than a waypoint. If you are at 1mg and the scales have barely moved, it does not mean the medicine is not working for you. It likely means you are not yet at the dose where meaningful pharmacological suppression of appetite takes hold for most people.

Wegovy's titration exists for a practical reason. Starting at 0.25mg and stepping up gradually reduces the intensity of gastrointestinal side effects (nausea, indigestion and similar) that GLP-1 receptor agonists can cause. The starting dose of 0.25mg is essentially a settling-in period. By 1mg you are past the gentlest steps, but you are still short of the 1.7mg step and well short of the 2.4mg maintenance dose where the clinical trial data was collected. Comparing your 1mg experience to a headline like "patients lost 15% of body weight" is comparing different chapters of the same story.

This is not a reason for frustration. It is, if anything, reassuring: the titration is working as intended, and your prescriber will be tracking progress with you at each review.

What does happen at 1mg, and what the trial programme tells us

The STEP 1 trial, the foundational study behind Wegovy's UK approval, randomised participants to 2.4mg weekly semaglutide (not 1mg) over 68 weeks. Average body-weight reduction was approximately 15%, and those figures are cited by NICE in its appraisal of semaglutide (TA875). The trial was not designed to isolate intermediate-dose outcomes, so there is no clean 1mg-specific result to quote.

What we do know from pharmacology is that GLP-1 receptor agonism becomes progressively more pronounced as the dose increases. At lower doses, effects on gastric emptying and satiety are present but partial. Many people on the titration schedule report a noticeable reduction in appetite kicking in more clearly at 1.7mg or 2.4mg. Some notice it earlier. Biology varies.

For the updated higher maintenance option, it is worth noting that in January 2026 a dedicated 7.2mg pen received MHRA approval, with trial data suggesting around 20.7% average weight loss at that dose. To understand what the preceding steps typically look like, you can review what people experience at the 0.5mg stage, which gives useful context for how outcomes build across the titration. The full Wegovy overview sets out how the dose ladder works from start to maintenance.

Side effects at the 1mg step: what tends to happen

For many people, the move from 0.5mg to 1mg is where GI symptoms become more noticeable for the first time. Nausea, loose stools, indigestion and a feeling of early fullness are the most commonly reported. The NHS semaglutide medicines page lists these alongside guidance on when to contact a doctor.

The practical experience varies a lot. Some people breeze through 1mg with little disruption; others find it the trickiest step before things settle. A useful pattern: symptoms tend to peak in the first week after a dose change and ease off before the next increase is due. Eating slowly, avoiding very fatty or rich meals, and staying well hydrated all help, your prescriber or the Patient Information Leaflet will guide you on the specifics.

One thing worth watching at this stage: if nausea is persistent and eating becomes genuinely difficult, that is a conversation to have with your prescriber before moving to the next dose. Staying at a given step longer is a legitimate clinical choice. You can read more about how the schedule is structured on the Wegovy doses page.

What 1mg results tell your prescriber, and what comes next

Your experience at 1mg is clinical information. How your body handles the dose, whether side effects have settled, and how your appetite and weight are responding all feed into the decision about when and whether to step up. A prescriber reviews these factors; it is not just a timer running to the next pen.

At each repeat order, a GPhC-registered prescriber at our pharmacy personally re-reviews your progress. That review is the point at which the titration pace is confirmed or adjusted. If you are curious how the later steps compare (particularly what the data shows at the 1.7mg step or at full 2.4mg maintenance) those pages set out the evidence for each stage separately.

The broader picture on costs, what treatment includes and how the private route compares to NHS access is covered on our weight-loss treatment overview. If you have specific questions about your own titration, our support team is available seven days a week, you can reach us via the contact page.

If you are not yet on treatment and want a clinical assessment to see whether Wegovy is appropriate for you, the right next step is to start your free consultation with one of our prescribers.